An official website of the United States government
Home
Name
Amtagvil
Alternate Names
Lifileucel
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
None
NSC Number
None
Primary Site
None
Histology
Melanoma
Remarks
February 16, 2024 FDA granted accelerated approval to lifileucel (Amtagvi), a tumor-derived autologous T cell immunotherapy, for adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 positive, a BRAF inhibitor with or without a MEK inhibitor. This treatment is also referred to as TIL therapy.
Coding
This drug should be coded
